ArticleCancer cell international2025
Non-invasive colorectal cancer biomarkers: HAND2 and GPM6A methylation in circulating tumour DNA.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide. Early detection is critical for improving patient outcomes. This study investigated the potential of circulating tumour DNA (ctDNA) methylation markers, specifically Heart and Neural Crest Derivatives Expressed 2 (HAND2) and Glycoprotein M6A (GPM6A), as novel non-invasive biomarkers for CRC detection and treatment monitoring.
methodsPlasma samples were collected from 40 CRC patients before and after treatment, as well as 40 healthy controls. Methylation levels of HAND2 and GPM6A in ctDNA were quantified using quantitative methylation-specific PCR (qMS-PCR).
resultsMethylation levels of HAND2 and GPM6A were significantly elevated in pre-treatment colorectal cancer (CRC) patients compared to post-treatment patients and healthy controls. Specifically, HAND2 methylation exhibited a statistically significant reduction following therapeutic intervention (pre-treatment: 55.75% ± 26.75 vs. post-treatment: 37.98% ± 22.93, p < 0.001), with no significant correlation observed between pre- and post-treatment levels (Pearson r = 0.1030, p = 0.53). Similarly, GPM6A methylation decreased markedly post-treatment (pre-treatment: 72.93% ± 18.06 vs. post-treatment: 49.48% ± 16.83, p < 0.001) yet demonstrated a statistically significant positive correlation between pre- and post-treatment values (Pearson r = 0.3181, p = 0.05). Receiver operating characteristic (ROC) curve analysis revealed robust diagnostic performance, with the combined HAND2 and GPM6A methylation model yielding an area under the curve (AUC) of 0.9213 (95% CI: 0.8569–0.9856, p < 0.001), surpassing the individual discriminative capacities of HAND2 (AUC = 0.8906) and GPM6A (AUC = 0.8881). Survival analysis leveraging the Cancer Genome Atlas (TCGA) dataset indicated a potential association between elevated methylation of both genes. It reduced survival probability, with a pronounced effect observed in rectal adenocarcinoma.
conclusionHAND2 and GPM6A methylation in ctDNA are promising non-invasive biomarkers for CRC detection and monitoring, outperforming the diagnostic accuracy of traditional markers such as CEA or CA19-9. Further research is needed to validate these findings in larger cohorts and investigate their potential as markers for treatment response and disease recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.